ABSTRACT
O
ral corticosteroids (OCS) are a mainstay of treatment for severe asthma and are widely used to manage asthma exacerbations. 1 Although quite efficacious in controlling asthma, OCS use may also contribute to a variety of adverse events (AE), including bone fractures, diabetes mellitus, infections, hypertension, and cataracts. 2 Corticosteroid toxicity is believed to be associated with both average dosage and cumulative duration of use. 3 For example, the fracture risk increases within 3-6 months of OCS therapy initiation, and using more than 5 mg of prednisolone or equivalent daily appreciably reduces bone mineral density. 4 One study found that more than 90% of those who filled Ն60 days of OCS during an 18-month span subsequently reported at least one AE, most commonly weight gain. 5 Another study found that lipodystrophy, insomnia, and neuropsychiatric disorders were the most-frequent adverse events. 6 Because of these risks, chronic OCS use is recommended only for patients with asthma whose disease cannot be controlled with both inhaled steroids (ICS) and long-acting ␤-agonists. 1 However, the incremental risks associated with OCS use across a broad range of known corticosteroid-related AEs have not been well elucidated, nor have specific levels of OCS use that confer excess risk been described. 3, 7 Our objective was to determine the incremental risk of clinical adverse events commonly associated with steroids in patients with asthma and with high OCS use.
METHODS

Study Design and Data Source
This matched cohort study used U.S. commercial health care claims to examine the risk of possible corticosteroid AEs between patients with asthma and high use of OCS and those who did not use OCS. The claims data base is Health Insurance Portability and Account-ability Act compliant and includes ϳ15 million annual commercially insured lives from across the United States. The data base does not contain information on patient race or body mass index, nor does it contain protected health information. It was exempt from institutional review board review.
Study Population and Time Frame
A 2-year observation period (2008 -2009) was used. By using a validated claims-based method for identifying patients with asthma, we included patients Ն18 years of age who had Ն2 medical claims with asthma as one of the listed diagnoses (International Classification of Diseases, Ninth Revision, Clinical Modification code 493.x) and had filled Ն2 asthma medications (Supplemental Appendix Tables 1 and 2 ) in 2008. 8 We excluded patients if they were not continuously enrolled during 2008 -2009, or if they used any intravenous (IV) corticosteroids, because the dose of IV medications could not be determined with the source data base.
We classified identified patients with asthma into "high-OCS" and "no-OCS" groups. High-OCS use was defined as Ն30 days of supply in a year, regardless of cumulative dose. This definition was derived from previously published data by using a national cohort of 37,123 commercially insured patients with asthma, in which patients with Ն30 total annual days of supply were exposed to a median total cumulative annual dose of OCS of 1260 mg compared with 250 mg in those with Ͻ30 total annual days of supply (Table 1 ). The total prednisone equivalent dose increased in that study with each category of days supply, from 250 mg in patients with Ͻ30 annual days of supply group, to 965 mg in the 30 -59 days of group, 1682 mg in the 30 -89 days of group, and 2700 mg in those with Ն90 days of supply. 9 To be categorized as high-OCS, the patients were required to be high-OCS users in both 2008 and 2009. Patients with low or intermediate OCS use used Ͻ30 days of supply of OCS in a year, regardless of the cumulative dose and were excluded from further analysis. Patients in the high-OCS and no-OCS groups were matched in a 1:1 ratio by age (in years), sex, and region. Because COPD has a known association with comorbidities, such as osteoporosis and infections 10, 11 that might also be attributed independently to OCS use, we stratified our results by the presence of COPD.
Study Variables
The main outcome of interest was the risk of possible corticosteroid-related AE, which was identified by using medical claims from 2008 to 2009. We focused on bonerelated conditions, pneumonia, opportunistic infections, hypertension, diabetes mellitus, glaucoma, cataracts, lipid disorders, obesity, and peptic ulcer disease, and these conditions were all identified by using International Classification of Diseases, Ninth Revision, Clinical Modification codes (Supplemental Appendix Table 1 ). The primary predictor variable was exposure to OCS, which we measured as the prednisone-equivalent dose in milligrams based on all medication fills in the study period. Additional variables included patient demographics as well as treatment-and disease-related characteristics. Usual physician specialty was defined as the specialty with the largest number of office visits with evaluation and management services during the study period. 1 An analogous measure was constructed for "usual asthma physician specialty" based on evaluation and management visits with an asthma diagnosis only. As a proxy for the general level of illness, we reported the number of chronic conditions calculated by using a previously validated method.
12 Asthma-related resource utilization was defined as any asthma-related (primary diagnosis of asthma) hospitalization or emergency department visit and the number of short-acting ␤-agonist prescriptions filled. Other variables included ICS and ophthalmic corticosteroid use.
Statistical Analysis
Descriptive statistics, including means (standard deviations), medians, and percentages, were reported for all measures, stratified by high OCS versus no OCS as applicable. We used 2 tests and t-tests to compare categorical and continuous variables, respectively. We compared For permission to copy go to https://www.oceansidepubl.com/permission.htm the prevalence of possible corticosteroid AEs between the high-OCS and no-OCS cohorts, with and without further stratification by COPD diagnosis. A logistic regression model was used to determine if remaining differences between groups on ICS exposure explained betweengroup differences in AE frequency. All data transformations and statistical analyses were performed by using SAS version 9.4 (SAS Institute, Cary, NC). All tests were two-sided, with a significance level of 0.05.
RESULTS
Patient Characteristics
We identified 188,085 patients with asthma, excluding 80,410 who were not continuously enrolled, 39,736 who were Ͻ18 years old, and 79 who used IV corticosteroids. We identified matches for 3604 of 3713 patients (97%) who met the definition of high OCS use. The final study group comprised these 3604 patients in the high-OCS group and their 3604 patients as the no-OCS matched controls (Fig. 1) . The mean age of the matched cohorts was 54.4 years, and 68.1% were female (Table 2 ). Approximately 44.9% had a diagnosis of COPD. Unmatched patient and provider-level characteristics are provided in Table 3 .
Matched Clinical Characteristics and Resource Utilization
After matching, age, sex, region, and COPD status were identical between the groups. Patients in the high-OCS groups had statistically significantly more chronic conditions than their counterparts in the no-OCS group (6.4 versus 5.4). The physician specialty that provided overall care and asthma-related care was statistically significantly different between that highand no-OCS groups (p Ͻ 0.001), with patients in the high-OCS group less likely to have a primary care physician provide their usual care (53.9% versus 65.2%) and less likely to provide their usual asthma care (44.0% versus 51.9%). Patients in the high-OCS group had a mean prednisone-equivalent dose exposure of 4592 mg during the study period, compared with 0 mg for the no-OCS group. They also tended to For permission to copy go to https://www.oceansidepubl.com/permission.htm fill more ICS and short-acting ␤-agonist prescriptions, used more ophthalmic steroids, and visited the emergency department more frequently, and they were hospitalized more often for asthma-related issues than patients in the no-OCS group.
Incremental Risk of AEs in High-OCS Users
Patients in the high-OCS group had a higher overall rate of possible corticosteroid-related AEs than patients in the no-OCSgroup (83.5% versus 78.1%, p Ͻ 0.001) (Table 4) , an incremental risk of 5.4%. Hyperten- For permission to copy go to https://www.oceansidepubl.com/permission.htm sion (62.9%), lipid disorders (55.2%), and diabetes (34.0%) were the three most common potential corticosteroid AEs identified in the high-OCS cohort. Individually, most potential AEs were seen in significantly higher proportions among patients versus the high-OCS group, including hypertension (62.9% in the high-OCS versus 56.9% in the no-OCS group), diabetes (34.0% versus 28.4%), pneumonia (28.4% versus 10.9%), obesity (19.4% versus 17.1%), osteoporosis (7.6% versus 4.3%), cataracts (6.8% versus 5.3%), and opportunistic infections (1.5% versus 0.4%) (cataracts, p ϭ 0.01; obesity, p ϭ 0.011; all others, p Ͻ 0.001). There were no significant differences in the rates of glaucoma and peptic ulcer disease, whereas lipid disorders were significantly less prevalent in patients in the high-OCS group than in patients in the no-OCS group (55.2% versus 60.7%; p Ͻ 0.001). The highest incremental risk among AEs was for pneumonia (17.5% higher in patients in the high-OCS group).
Incremental Risk of AEs in Patients in the High-OCS Group by COPD Status
Patients were stratified by the presence or absence of COPD (Table 4 ). The incremental risk of any potential AE in patients in the high-OCS group was 6.4% higher among patients without COPD (75.9% in patients in the high-OCS group versus 69.5% in the no-OCS group, p Ͻ 0.001). The risk was increased by 4.1% in those with COPD (92.9% versus 88.8%, p Ͻ 0.001). The pattern of increased risk in both patients with COPD and those without COPD was nearly identical to the overall comparison between all patients in the high-OCS and no-OCS groups. Risks of potential AEs were significantly higher in patients in the high-OCS group compared with nonusers for pneumonia (increased by 12.2% in patients without COPD and by 23.9% in patients with COPD), bone-related conditions (without COPD increased 3.2%, with COPD increased 5.3%), and opportunistic infections (without COPD increased 1.1%, with COPD increased 1.2%) Hypertension, diabetes, and obesity were all statistically significantly more prevalent among users of high doses OCS in both the COPD and non-COPD groups. Lipid disorders were significantly less prevalent among users of high doses OCS users than nonusers in both COPD and non-COPD groups.
DISCUSSION
The risk of a broad range of potential AEs known to be associated with OCS use is statistically significantly higher in patients with asthma who fill 30 days or more of OCS per year for 2 years than in patients who did For permission to copy go to https://www.oceansidepubl.com/permission.htm not use OCS. The risk of any of the studied potential AEs is statistically significantly elevated in both patients with COPD and those without COPD who used high amounts of OCS. The magnitude of risk in both patients with COPD and those without COPD (an increase of 4.1% in COPD and 6.4% in non-COPD) is similar to what has been seen in other studies. 3, 4 The results are biologically plausible given what is known about the impact of corticosteroids on immunity, bone formation, endocrine function, and other body systems. As a result of their known risks, OCS are recommended only for acute exacerbations and for patients who have inadequate response to inhaled ICS and inhaled long-acting ␤-agonists and other long-term controllers. However, we found OCS use to be common: 60% of patients with asthma filled at least one OCS prescription over a 2-year period, and 5.4% filled at least a 30 days of supply each year for two consecutive years. Corticosteroids inhibit T-cell activation and suppress proinflammatory cytokine production, which leads to significant immunosuppressive effects. 4 Not surprisingly, the risk of infectious conditions showed the largest increase with OCS use. The risk of pneumonia in patients who use high doses of OCS is 2.3-to 3.5-fold that of the patients who do not use OCS, and the risk of opportunistic infections is 3.4-to 4.7-fold that of nonusers. Although we could not directly establish the severity of these opportunistic infections, we limited our analysis to those conditions recognized as most serious (e.g., severe or disseminated candidiasis, disseminated herpes zoster, severe herpes simplex) (Supplemental Appendix Table 1 ).
An unexpected finding was the higher rate of lipid disorders in patients in the non-OCS group compared with the high-OCS group. We considered four possible explanations for this finding. First, there might be an unmeasured covariate that is unequally distributed between the groups. For example, some risk factor for lipid disorders might be more common in the non-OCS group of users (e.g., obesity, family history of hyperlipidemia). Statins have been demonstrated in large cohort studies to be prescribed more often in patients with higher cardiovascular risk. 13, 14 If the cardiovascular risk factor did not appear in claims, we would be unable to identify or adjust for it. Second, this could be a chance finding and not reflective of an actual underlying difference between the groups (the identification of a statistically significant difference at the p Ͻ 0.05 level means the probability is 5% that the finding occurred by chance). Third, there may be a direct, causal relationship between the use of OCS and lower lipids (e.g., OCS use reduces lipid levels). However, we found no literature to support this proposition, and, indeed, some evidence refutes it. Fourth, the direction of causality could be reversed, and physicians may be reluctant to prescribe OCS to patients with elevated lipids, perhaps because of concern over the potential adverse cardiovascular effects of OCS on a population already at risk. A study designed to test this hypothesis would require a different design than the one we undertook and could be considered in the future.
Although OCS use is known to carry risk, there has been relatively little research that estimates the magnitude of the risk specifically in patients with asthma. Zazzali et al. 15 demonstrated that, among adult patients with asthma, every 1000 mg increase in OCS was associated with a 3% higher risk of osteoporosis, 2% higher risk of fracture, and 2% higher risk of cataracts. The overall prevalence of AEs in this population is consistent with previous research that used different study designs. 6, 7 Our results appear to be consistent with previous epidemiologic studies that examined comorbidities and resource utilization in similar populations. 16, 17 A key strength of our study was that we were able to implement a practical, clinically relevant definition of high OCS use (Ն30 days of supply) to measure the outcomes of patients with asthma. This threshold was established in an exploratory analysis of more than 37,000 patients with asthma. 9 A systematic review of the cumulative medical and economic burden of OCS use concluded that a dose-response relationship exists between higher OCS doses and the risk of various AEs but that variation based on specific OCS therapies has not been well characterized. 2 Potential areas for future research include further confirmation of what is confirmation of "high" or "low" OCS dose thresholds, the definitions of which remain controversial. 5, 6, 18, 19 Validation of our findings with multiple levels of OCS use and/or other patient populations (including Medicaid patients and other commercially insured patients) would be valuable.
The study had limitations. Observational studies cannot establish causation, and we have no direct evidence that observed OCS prescription fills resulted in the observed increase in AEs. Distinguishing between an underlying (preexisting) comorbidity and a true AE that results from OCS use may be difficult in any setting, 18 and is particularly difficult when using administrative claims. We used a matched and stratified study design to control for potential confounding. The resulting difference in prevalence should represent the effect of the independent variable. The prevalence of potential AEs in patients who are high OCS users was 83.5% overall (75.9% without COPD, 92.9% with COPD), consistent with previously published reports by Curtis et al. 6 (90%) and Fardet et al. 7 (up to 63.0%). Matching is only possible on variables available in the data base, and claims do not contain many variables, which may have confounded our analysis. Smoking, which increases the risk of a certain number of the observed AEs, is not coded reliably, and race and body mass index are not coded at all. So, for For permission to copy go to https://www.oceansidepubl.com/permission.htm example, if smokers with COPD were more likely to be prescribed OCS, then our results could be biased. Studies that use clinical data would be useful to confirm our findings. We did attempt to control for asthma severity because users of OCS and nonusers would be expected to differ substantially in severity. However, the matched groups differed significantly in the number of ICS canisters used. To control for potential confounding by ICS use, we conducted a regression model after matching to control for ICS (data not shown). The model confirmed both that ICS did not predict AEs and that there was statistically significant increase in the odds of AE in the users of high amounts of OCS, even after controlling for ICS.
Other limitations of this study were those inherent in claims data bases, including coding errors and a lack of clinical detail. Health care claims data bases are retrospective and collected for billing and not for research purposes. Claims data generally lack information on dosing of IV medications, such as detail on IV corticosteroid dose. We, consequently, excluded 79 patients who used IV steroids, although these patients comprised too small a sample to have meaningfully affected the results. Finally, the data base does not contain uninsured patients, who may have different demographics, comorbidities, and medication utilization patterns. 19 In conclusion, patients with asthma who filled OCS prescriptions that covered 30 days a year for 2 years had a significantly greater prevalence of potential corticosteroid-related AEs, such as pneumonia and bonerelated conditions, than age, sex, and COPD-status matched patients who filled no OCS prescriptions. The incremental risk of AEs overall is 5.4% in patients with high OCS use. Rates of potential AEs are statistically significantly higher both in patients with asthma and with COPD and in those patients without COPD. Long-term OCS use adversely affects multiple organ systems. Reducing corticosteroid use by better adherence to expert guidelines 1 and by developing corticosteroid-sparing treatments with comparable or improved efficacy and effectiveness are both critical steps to minimize the AEs of therapy. Research that builds on our definition of high OCS use may provide the groundwork for more specific policy recommendations regarding measures to prevent or screen for potential AEs in patients with asthma who use high doses of OCS.
